American biotech company Becton, Dickinson and Company (BD) (NYSE: BDX) announced on Wednesday a new self-collection solution for human papillomavirus (HPV) testing in markets outside the United States.

The solution enables at-home sample collection and integrates with the BD COR System, which automates laboratory processing using advanced robotics.

Certified under the In Vitro Diagnostic Medical Device Regulation (IVDR) in Europe, the swab offers a safe, simple, and non-invasive method for collecting samples without liquids or complex tools. Its stability supports mailing from home to laboratories, reducing logistical challenges and broadening access to cervical cancer screening.

In laboratories, the self-collected swabs are designed to require no manual preparation, allowing clinical technologists to focus on higher-value work as well as maintaining specimen integrity through minimal manual intervention. The BD COR System then automates the entire process, from preparation to analysis and reporting.

Key workflow features include onboard rehydration technology that removes the need for manual prep, a unified barcode-driven process for both clinician and self-collected samples, and up to 30 days of dry sample stability using the Copan FLOQSwab.

BD said the Onclarity HPV Self-Collection with Onboard Rehydration Fully Automated Solution will be commercially available in IVDR-recognised markets in the coming months, supporting public health initiatives to increase cervical cancer screening participation.